Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Pfizer's Sasanlimab?
Sasanlimab is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Non Muscle Invasive Bladder Cancer...
Sasanlimab by Pfizer for Ovarian Cancer: Likelihood of Approval
Sasanlimab is under clinical development by Pfizer and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...
Sasanlimab by Pfizer for Sarcomas: Likelihood of Approval
Sasanlimab is under clinical development by Pfizer and currently in Phase I for Sarcomas. According to GlobalData, Phase I drugs...
Sasanlimab by Pfizer for Solid Tumor: Likelihood of Approval
Sasanlimab is under clinical development by Pfizer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Sasanlimab by Pfizer for Non-Small Cell Lung Cancer: Likelihood of Approval
Sasanlimab is under clinical development by Pfizer and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Sasanlimab by Pfizer for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Sasanlimab is under clinical development by Pfizer and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....
Sasanlimab by Pfizer for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval
Sasanlimab is under clinical development by Pfizer and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC). According to...
Risk adjusted net present value: What is the current valuation of Pfizer's Sasanlimab?
Sasanlimab is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Non Muscle Invasive Bladder Cancer...